Oruka Therapeutics Shares Rise on Positive Clinical Trial Results for Psoriasis Treatment
Oruka Therapeutics (NASDAQ:ORKA) shares hit a record high after its psoriasis treatment candidate, ORKA-001, achieved a 63.5% success rate in a clinical trial. The trial showed higher skin clearance rates compared to other IL-23p19 inhibitors and no serious adverse effects. The stock rose 10.66% to $76.39 following the announcement.
Topics: clinical trials pharmaceuticals psoriasis treatment stock price movement